Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$1.2 million.

  • BioNexus Gene Lab's Free Cash Flow rose 3103.25% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year increase of 1680.19%. This contributed to the annual value of -$2.5 million for FY2024, which is 2483.45% down from last year.
  • According to the latest figures from Q3 2025, BioNexus Gene Lab's Free Cash Flow is -$1.2 million, which was up 3103.25% from -$759366.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Free Cash Flow registered a high of $481728.0 during Q4 2021, and its lowest value of -$1.8 million during Q3 2024.
  • In the last 5 years, BioNexus Gene Lab's Free Cash Flow had a median value of -$116620.0 in 2023 and averaged -$356034.1.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 11172.41% in 2021, then plummeted by 130973.3% in 2025.
  • Over the past 5 years, BioNexus Gene Lab's Free Cash Flow (Quarter) stood at $481728.0 in 2021, then dropped by 4.57% to $459712.0 in 2022, then tumbled by 270.42% to -$783463.0 in 2023, then surged by 109.47% to $74181.0 in 2024, then crashed by 1775.56% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$759366.0 for Q2 2025, and -$833124.0 during Q1 2025.